Physician profile
Tamarae Dobbs
NPI 1720251085
$8,307.92
in general payments reported to CMS, 2019-2025
24 companies · $2,040 in 2025
The $2,040 reported for 2025 was more than what 94% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $944 · 2022: $1,260 · 2023: $1,658 · 2024: $2,405 · 2025: $2,040.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,810 · Education: $293.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,810.37 |
| Education | $293.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,078.76 | 2021-2025 | Tremfya, Stelara, Simponi |
| Abbvie INC. | $1,011.98 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $857.31 | 2021-2025 | Ilumya |
| Regeneron Healthcare Solutions, INC. | $842.46 | 2021-2025 | Dupixent, Libtayo |
| Leo Pharma INC. | $761.15 | 2022-2025 | Adbry, Anzupgo |
| Dermavant Sciences, INC. | $746.94 | 2023-2024 | Vtama |
| Genzyme Corporation | $668.17 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $434.24 | 2021-2024 | Sotyktu |
| Galderma Laboratories, L.P. | $424.56 | 2021-2025 | Nemluvio |
| Novartis Pharmaceuticals Corporation | $275.14 | 2021-2025 | |
| Lilly USA, LLC | $234.73 | 2021-2024 | Taltz, Olumiant, Ebglyss |
| Ucb, INC. | $199.90 | 2021-2025 | Bimzelx, Cimzia |
| Incyte Corporation | $138.34 | 2022-2024 | Opzelura |
| Almirall LLC | $131.23 | 2022-2025 | Seysara, Klisyri |
| Amgen INC. | $84.88 | 2024-2025 | Otezla, Otezla |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $80.93 | 2021-2024 | |
| Mayne Pharma Commercial LLC | $72.11 | 2021-2024 | |
| Arcutis Biotherapeutics, INC. | $60.11 | 2024-2025 | Zoryve |
| Biofrontera INC. | $53.91 | 2023-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Genentech USA, INC. | $45.54 | 2021-2022 | |
| Allergan, INC. | $44.92 | 2021-2022 | |
| Springworks Therapeutics, INC. | $23.42 | 2025 | Gomekli |
| Organon LLC | $20.36 | 2025 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $16.83 | 2025 | Siliq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamarae Dobbs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.